Seeking Alpha

Acadia Pharmaceuticals (ACAD -10.2%) crashes after disclosing it's discontinuing development for...

Acadia Pharmaceuticals (ACAD -10.2%) crashes after disclosing it's discontinuing development for its AM-831 schizophrenia drug after it failed to "meet pre-determined criteria for further development in Phase I testing." AM-831 was being developed in partnership with Japan's Meiji Seika Pharma.
Comments (1)
  • Deja Vu
    , contributor
    Comments (1374) | Send Message
     
    That is a real tragedy. Mental health drugs do not have a paying clientele clamoring for them.
    13 Jul 2012, 01:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs